GET DAILY SIGNALSCognition Therapeutics (CGTX) Narrows Q3 Loss to $4.1 Million With FDA Alignment on Streamlined Phase 3
Key Takeaways
- Cognition Therapeutics reported a third quarter 2026 net loss of $4.1 million, or $(0.04) per share, beating the $(0.07) per share consensus estimate.
- Research and development (R&D) expenses rose to $5.1 million, while general and administrative (G&A) costs fell to $2.3 million year over year.
- Cash, cash equivalents, and restricted cash totaled $31.5 million, with the company extending its cash runway into the fourth quarter of 2027.
- Management said it reached alignment with the U.S. Food and Drug Administration (FDA) on a smaller, lower-cost Phase 3 design for zervimesine (CT1812) in dementia with Lewy bodies (DLB).
- The company separately disclosed a Nasdaq notice that its stock traded below the $1.00 minimum bid price for 30 consecutive business days.
Earnings Context and Why It Matters
CGTX is a clinical-stage biopharmaceutical company with no product revenue, which means its quarterly earnings matter less for the income statement and more for the clinical and regulatory signals they provide. I track each report to gauge how quickly cash is being consumed and whether its lead candidate, zervimesine, is advancing toward a registrational trial. This quarter stood out because management announced alignment with the FDA on a streamlined Phase 3 design in DLB, clarifying the regulatory path after months of uncertainty. At the same time, the stock's decline below the $1.00 Nasdaq threshold introduces a listing-compliance risk that focuses attention on capital raising and trial execution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Cognition Therapeutics reported a third quarter 2026 net loss of $4.1 million, or $(0.04) per basic and diluted share, narrowing from a net loss of $4.9 million, or $(0.06) per share, in the year-ago quarter. The result beat the $(0.07) per share consensus estimate. R&D expenses rose to $5.1 million from $3.8 million, driven by higher trial activities with contract research organizations, while G&A expenses declined to $2.3 million from $2.6 million. Grant income climbed to $3.0 million from $1.2 million, which more than offset the wider operating loss. The company ended the quarter with $31.5 million in cash, cash equivalents, and restricted cash, plus $18.2 million in remaining National Institute on Aging (NIA) grant funds, and extended its expected cash runway into the fourth quarter of 2027.
Market Reaction and Investor Sentiment
The stock has been under sustained pressure, with shares trading near $0.68, down roughly 38% from the $1.10 level following the prior quarter's report. On November 3, 2026, the company received a deficiency letter from Nasdaq because its closing bid price had remained below the $1.00 minimum for 30 consecutive business days. The notice has no immediate effect on listing, and the company has 180 days, until May 3, 2027, to regain compliance. While the narrower-than-expected loss and FDA alignment are constructive developments, investor sentiment remains cautious, reflecting concerns about how the still-unfunded pivotal trial will be financed and the potential for further dilution. The per-share improvement also benefited from a larger share count, which has diluted existing holders.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is the zervimesine program. Management said it has aligned with the FDA on a Phase 3 design in mild-to-moderate DLB, using a measure of hallucinations and delusions as the primary endpoint and a daily-living scale as a key secondary endpoint. The trial is expected to enroll fewer than half of the roughly 750 patients originally contemplated and to cost less than the approximately $150 million initially estimated.
However, the pivotal study remains unfunded, and the company is targeting a mid-2027 start. Investors should watch for news on financing, partnerships, or other capital-raising steps, as these will shape both dilution risk and the company's ability to execute the trial.
A separate catalyst is the START Phase 2 study of zervimesine in early Alzheimer's disease. That 545-patient trial is fully enrolled and funded with non-dilutive NIA capital, with top-line results expected in the second half of 2027 — timing that coincides closely with the projected end of the company's cash runway.
Finally, monitoring the bid price and any steps to restore Nasdaq compliance, such as a potential reverse stock split, will be important for assessing shareholder risk. All of these factors should be viewed in the context of the company's broader effort to advance a disease-modifying therapy while preserving its balance sheet.
Exploring AI Tools for Biotech Analysis
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter comparable names in the biotechnology sector and review technical patterns alongside fundamentals. It helps surface ideas that might otherwise require hours of manual work, especially when evaluating smaller clinical-stage companies like this one. The tool has become a regular part of how I cross-check sector trends before digging deeper into specific catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CGTX turns negative, indicating new downward trend
CGTX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned negative. In 94 of the 104 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CGTX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CGTX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CGTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGTX advanced for three days, in 164 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.830) is normal, around the industry mean (2.788). P/E Ratio (-3.738) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CGTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement